Approxima, a MedTech startup pioneering a percutaneous right ventricular reshaping technology for tricuspid regurgitation (TR), has secured a €7.3 million financing round. The investment was co-led by ENEA Tech e Biomedical and Panakès Partners, with continued backing from existing investors, including Club degli Investitori and other business angels.
Founded in 2020 as a spin-off from the Department of Electronics, Information and Bioengineering – Politecnico di Milano by Prof. Riccardo Vismara and Prof. Gianfranco Beniamino Fiore along with Michal Jaworek and Edoardo Maroncelli, Approxima is developing a breakthrough solution to address TR at its root cause—right ventricular dilation. The newly raised funds will support final preclinical verifications and pilot clinical trials, bringing the technology closer to patients in need.
TR is a severe and under-treated condition that affects over 250,000 new patients annually in Europe and the U.S., predominantly women over 60. It leads to poor quality of life, frequent hospitalizations, and a staggering 36% one-year mortality rate. Due to the high risks of open-heart surgery, most patients are left with limited medical therapy, underscoring the urgent need for a minimally invasive alternative.
Approxima’s technology offers a paradigm shift in TR treatment. By reshaping the right ventricle rather than focusing solely on the tricuspid valve, it restores valve function while preserving future treatment options, including valve repair or replacement. The straightforward percutaneous procedure not only enhances valve performance but also improves overall right ventricular function, addressing the disease more holistically.
With this latest funding, Approxima is set to accelerate its journey toward transforming TR treatment, offering new hope to thousands of patients worldwide.